Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via email.
October 14
Columbia Laboratories to Present October 21st at NewsMakers in the Biotech Industry Conference
Bristol-Myers Squibb Foundation Announces Six New Grants to Bridge Gaps in Cancer Awareness, Prevention and Care in Central and Eastern Europe
Celldex Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
October 13
Cyclacel Announces Data Safety Monitoring Board Recommendation To Continue The Seamless Phase 3 Trial Of Sapacitabine
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Virological and Immunological Efficacy Versus the Efavirenz Regimen at 192 Weeks of Treatment in Previously Untreated Adults with HIV-1
Nominations Sought for First SAFE-BioPharma Digital Identity Awards
Derma Sciences Launches MEDIHONEY® Gel at the Fall Symposium on Advanced Wound Care 2011
EKR Therapeutics Announces Senior Management Change
Aegerion Pharmaceuticals to Announce Third-Quarter 2011 Financial Results on Thursday, October 27
October 12
Celgene Corporation to Announce Third Quarter 2011 Results on October 27, 2011
STENTYS Self-Apposing Stents in “Perfect Apposition to Vessels” After Treating Patients with Heart Attacks
The Medicines Company to Announce Third Quarter 2011 Financial Results on Wednesday, October 26, 2011
October 11
Immunomedics Awarded U.S. Patent For Cytokine-Antibody Complexes
Soligenix Announces Formation of Pediatric Crohn’s Disease Medical Advisory Board
Bristol-Myers Squibb Foundation Announces Collaboration with World Health Organization’s Stop TB Department to Strengthen Community Based Care of Tuberculosis Including HIV Co-Infection in Five African Countries
Advaxis Granted Pre-IND Meeting with FDA for ADXS-HER2, an Immunotherapy for HER2 Expressing Cancers
Rutgers Launches $1M Fund to Encourage Disruptive Innovation
October 10
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
October 7
CorMedix to Host Conference Call on Recent Developments
October 6
Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene’s Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis
Unigene’s Leading Peptide Development Expertise Endorsed with Strategic Equity Investment of Up To $6 Million by Industry Legend Dr. Claus Christiansen
Unigene to Host Live Conference Call and Webcast to Discuss Collaboration with Nordic Bioscience and Formation of Joint Development Vehicle
Merck Announces Retirement of Chairman and Former CEO Richard T. Clark
Rutgers-Affiliated Startup Gets Funding for Breast Cancer Analysis Tools
October 5
Alliance Life Sciences Releases White Paper Aimed at Process Integration in Reorganizations, Mergers and Acquisitions
October 4
Merck Adds New Medication Adherence Resources to Consumer Web Site
Antares Pharma Granted New U.S. Patent Covering VIBEX™ Injector Technology
FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor
October 3
The Medicines Company Launches New Formulation of Cleviprex(R) (Clevidipine) Injectable Emulsion
The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With Teva
Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX® (alendronate sodium)
September 30
Roche Adds to Nutley Campus with Manufacturing Hub
Merck to Hold Third-Quarter 2011 Sales and Earnings Conference Call on October 28
Merck Announces New Data Analyses for VICTRELIS™ (boceprevir) will be Presented at The American Association for the Study of Liver Diseases 2011 Annual Meeting
Bristol-Myers Squibb to Present New Data Demonstrating Company’s Leadership in Liver Disease at The Liver Meeting® / AASLD Annual Meeting
CorMedix Announces Strategic Changes Primary Focus on European Approval of Neutrolin® Executive Management Changes
September 29
CorMedix Announces FDA Designation for Neutrolin (CRMD003)
Durata Therapeutics Initiates Enrollment in DISCOVER-2, Second Phase 3 Study of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Sanofi US Launches healthFORWARD 2.0
September 28
Merck Names Cuong Viet Do as Chief Strategy Officer
Bauer LLC Demonstrates an Improved Approach to Graph Cannulation for Dialysis Patients with Grafts
September 27
MicroDose Therapeutx Begins Phase 1 Trialof MDT-637 for Treatment of RespiratorySyncytial Virus
September 26
SwabCap to Be Focus of Four Presentations at AVA Conference
NPS Pharmaceuticals Appoints Eric Pauwels as Chief Commercial Officer
Contract Research Organization DSP Clinical Research Achieves 1,266 Ranking on Inc. 500/5000 List; Fourth Consecutive Year DSP Earns Recognition
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
September 23
Helsinn Group and Eisai Inc. Announce Start of Phase III Clinical Program of Oral Fixed-Dose Combination of Netupitant/Palonosetron (300 mg/0.50 mg) for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Celgene Regulatory Update on REVLIMID(R)
Walgreens Take Care Health Systems and Sanofi US Open On-site Medical Center and Pharmacy
September 22
Columbia Laboratories Extends Stockholder Rights Plan to Preserve Use of Net Operating Losses under Section 382
Bristol-Myers Squibb and Ambrx Announce Collaboration for Novel Biologics Programs in Diabetes and Heart Failure
Enzon Announces Reduction in Force to Align Operations with Research and Development Activities
Immunomedics Announces Partial Clinical Hold on Clivatuzumab Tetraxetan Clinical
Trial
Cyclacel Pharmaceuticals Receives Deficiency Notice from NASDAQ Global Select Market
The Medicines Company to Participate in the Jefferies 2011 Global Healthcare Conference in London
September 21
Unigene Divests Non-Core Asset and Focuses Resources on High Valuation Drug Development and Peptide Drug Delivery Opportunities – Assigns Site Directed Bone Growth Patent Portfolio to Leading Researcher
Merck Chief Medical Officer to Discuss the Future of Innovation at Biotech 2011
Celgene Corporation to Present at JMP Securities Healthcare Conference 2011
September 20
First Patients Enrolled in the U.S. OPEN Clinical Trial of the FlexStent® Femoropopliteal SE Stent System
Bristol-Myers Squibb and Ono Enter into Strategic Agreement for Anti-PD-1 Antibody, BMS-936558/ONO-4538, and ORENCIA® (abatacept)
Merck Joins Global Fight to Help Save Women’s Lives During Pregnancy and Childbirth President and CEO Ken Frazier Announces 10-Year, $500 Million Mobilization
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer Andrew I. Koven Also Joins Neurologix as Company President and Chief Administrative Officer
Bristol-Myers Squibb Announces Dividend
September 19
Unigene’s Industry Leading, Proprietary Oral Delivery and Recombinant Manufacturing Technology Platforms are Further Validated with Positive Phase 3 Safety and Efficacy Data for OSTORA(TM)
Rutgers Focuses on Business Partnerships
Aestus Therapeutics and Prosidion Ltd Sign License Agreement for Novel Chronic Pain Therapeutic
ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Merck’s ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Efficacy and Tolerability in an Observational Trial in a Diverse Population of Adults with HIV-1 Regardless of Gender or Race
September 16
NPS Pharmaceuticals Highlights Hypoparathyroidism Data to Be Presented at Annual Meeting of American Society for Bone and Mineral Research
ONGLYZA™ (saxagliptin) When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels (HbA1c) Over 52 Weeks in Investigational Study Extension
